

TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth

Xinsheng Gao¹ and Duojia Pan^{1,2}

¹Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9040, USA

Tuberous sclerosis is a human disease caused by mutations in the *TSC1* or the *TSC2* tumor suppressor gene. Previous studies of a *Drosophila* *TSC2* homolog suggested a role for the *TSC* genes in maintaining DNA content, with loss of *TSC2* leading to polyploidy and increased cell size. We have isolated mutations in the *Drosophila* homolog of the *TSC1* gene. We show that *TSC1* and *TSC2* form a complex and function in a common pathway to control cellular growth. Unlike previous studies, our work shows that *TSC1*⁻ or *TSC2*⁻ cells are diploid. We find that, strikingly, the heterozygosity of *TSC1* or *TSC2* is sufficient to rescue the lethality of loss-of-function insulin receptor mutants. Further genetic analyses suggest that the *TSC* genes act in a parallel pathway that converges on the insulin pathway downstream from *Akt*. Taken together, our studies identified the *TSC* tumor suppressors as novel negative regulators of insulin signaling.

[Key Words: Cell size; tumor suppressor; insulin signaling; Akt]

Received April 3, 2001; revised version accepted April 16, 2001.

During metazoan development, cell-intrinsic and cell-extrinsic factors must act coordinately to specify the characteristic size of diverse cell types (for review, see Su and O'Farrell 1998; Stocker and Hafen 2000). An intrinsic factor that contributes to cell size is DNA content, and cell size correlates with ploidy in various species (Su and O'Farrell 1998). On the other hand, it has long been appreciated that cell-extrinsic factors such as hormones, growth factors, and nutrition play important roles in growth control at the organismal level (for review, see Conlon and Raff 1999). Thus a challenge is to understand how cell-intrinsic and cell-extrinsic factors coordinately control cellular growth and how changes in such regulation lead to pathological conditions such as cancer.

One of the hormone-mediated pathways that plays a pivotal role in cellular growth involves insulin or insulin-like growth factors (IGF) (for review, see Proud and Denton 1997). Biochemical studies have shown that on binding of insulin or IGFs, insulin receptor (InR) or IGF receptors recruit phosphoinositide 3-kinase (PI3K) to the membrane, either directly or through insulin receptor substrates (IRS) as intermediates. Phosphorylation of the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP₂) by PI3K produces the second messenger phosphatidylinositol 3,4,5-triphosphate (PIP₃), which activates Akt, a Ser/Thr kinase. Akt and another Ser/Thr kinase encoded by the *TOR* (target of rapamycin) gene ultimately control the phosphorylation of two downstream effectors, p70 S6 kinase (S6K) and 4E-binding protein (4E-

BP), which are involved in translational control (for review, see Thomas and Hall 1997; Sonenberg and Gingras 1998; Schmelzle and Hall 2000). Phosphorylation of S6K increases its kinase activity toward the ribosome S6 subunit, leading to increased translation of 5' terminal oligopyrimidine tract (TOP) mRNAs that largely encode components of the translational apparatus such as ribosomal proteins. Phosphorylation of 4E-BP releases the eukaryotic initiation factor 4E (eIF4E) from the inactive eIF4E/4E-BP complex, permitting eIF4E to function in translation initiation. A well-known negative regulator of this pathway is the PTEN tumor suppressor, which functions as a phosphatase to convert PIP₃ to PIP₂ (for review, see Cantley and Neel 1999). The importance of insulin signaling in growth control has been elegantly demonstrated by recent genetic studies from *Drosophila*. Loss-of-function mutations in *Drosophila* homologs of components of the insulin pathway, including *InR*, *IRS*, *PI3K*, *Akt*, *TOR*, and *S6K*, all result in decreased cell size, and overexpression of *PI3K*, *Akt*, and *S6K*, or loss of the negative regulator *PTEN*, result in increased cell size (Chen et al. 1996; Böhni et al. 1999; Goberdhan et al. 1999; Huang et al. 1999; Montagne et al. 1999; Verdu et al. 1999; Weinkove et al. 1999; Gao et al. 2000; Oldham et al. 2000; Zhang et al. 2000).

Tuberous sclerosis (TSC) is an autosomal dominant disorder that affects 1 in 6000 individuals (for review, see Young and Povey 1998). This disease is characterized by the widespread development of benign tumors termed hamartomas, which frequently lead to skin rashes, seizures, and mental retardation. TSC is caused by a mutation in either the *TSC1* or *TSC2* tumor suppressor gene.

²Corresponding author.

E-MAIL dpan@mednet.swmed.edu; FAX (214) 648-8885.

Article and publication are at www.genesdev.org/cgi/doi/10.1101/gad.901101.

TSC2 encodes a putative GTPase-activating protein (GAP), and *TSC1* encodes a novel protein containing two coiled-coil domains (The European Chromosome 16 Tuberos Sclerosis Consortium 1993; van Slegtenhorst et al. 1997). The *TSC1* and *TSC2* proteins have been shown to form a complex in mammalian cells (van Slegtenhorst et al. 1998; Nellist et al. 1999) and have been proposed to control various cellular functions including cell cycle (Soucek et al. 1997, 1998), endocytosis (Xiao et al. 1997), cell adhesion (Lamb et al. 2000), and transcription (Henry et al. 1998). However, it is not clear how these potential functions are used during normal development and how mutations of the *TSC* genes result in benign tumors.

Although animal models lacking *TSC1* have not been reported until now, studies of animal models lacking the *TSC2* gene have provided insight into the function of the *TSC* genes in development. The Eker rat strain contains a germline insertion mutation in the rat *TSC2* gene, which causes a premature truncation of the *TSC2* protein (Kobayashi et al. 1997; Rennebeck et al. 1998). Murine models lacking *TSC2* have also been generated by gene targeting (Kobayashi et al. 1999; Onda et al. 1999). In these models, homozygous *TSC2* mutants are embryonic lethal, whereas heterozygous carriers are prone to tumor formation. Recently, *Drosophila* homologs of *TSC1* and *TSC2* were reported (Ito and Rubin 1999). Ito and Rubin showed that cells lacking *gigas*, the *Drosophila* homolog of *TSC2*, are increased in cell size. They further suggested that the increased size of the *gigas* mutant cells is due to a failure to enter M phase at the end of imaginal disc development, resulting in polyploidy and, consequently, increased cell size (Ito and Rubin 1999). Given that such an increase in DNA content has not been reported in any *TSC* benign tumors in vertebrates, the described *gigas* mutant phenotype might potentially reflect the uniqueness of *Drosophila* development. In that aspect, studies of *Drosophila* mutants lacking the *TSC1* gene could complement the analysis of the *gigas* mutants. For simplicity, *TSC1* and *TSC2* are used throughout the rest of the paper to refer to the *Drosophila* *TSC1* and *TSC2* homologs unless otherwise specified.

Here we report the first animal model lacking the *TSC1* gene. We show that *TSC1* and *TSC2* form a complex in *Drosophila* cells and function in a common pathway to control cellular growth. We further show that the *TSC* genes act in a parallel pathway that converges on the insulin pathway downstream from *Akt*. Our studies identified the *TSC* tumor suppressors as novel negative regulators of insulin signaling.

Results

Isolation of *TSC1* mutants

We used the FRT/FLP recombination system (Xu and Rubin 1993) to screen the *Drosophila* genome for mutations that affect cell size. Two lethal mutations were recovered on the right arm of the third chromosome that

produced enlarged cells in mutant clones in the eye and wing. Both mutants die around embryo-larval transition without gross morphological defects. These mutations were localized to the 95D7-11; 95E8 region by deficiency mapping. This region contains a *Drosophila* homolog of the mammalian *TSC1* gene (Ito and Rubin 1999). Given that mutations of the *Drosophila* *TSC2* homolog *gigas* lead to a similar increase in cell size and that mutations in *TSC1* or *TSC2* result in the same disease in humans, we investigated whether our mutations at 95D-E disrupted the *Drosophila* *TSC1* homolog. DNA sequencing analysis revealed point mutations in both alleles (Fig. 1B). *TSC1*¹² has a single-base deletion that causes a frameshift, truncating the protein at amino acid 896. This mutation is predicted to delete part of the coiled-coil domains of the *TSC1* protein, which have been implicated in binding to *TSC2* (van Slegtenhorst et al. 1998). Another allele, *TSC1*²⁹, contains a single-base nonsense mutation (C to T) that replaces amino acid 61 (Gln) with a stop codon. This mutation is predicted to be a null allele because it truncates most of the protein. A 4.7-kb construct containing only the *TSC1* genomic DNA was able to fully rescue *TSC1*¹² and *TSC1*²⁹ homozygotes to viable and phenotypically wild-type animals, confirming that the two mutations indeed disrupted




Figure 1. Structure of the *TSC1* locus and predicted structure of the TSC proteins. (A) Genomic structure of the *TSC1* locus. The *TSC1* gene is located between *CG6129* and *sec10* on 3R. The exons are indicated with thick lines and the introns are shown as thin lines connecting adjacent exons. The transcription start site is indicated with a single line with an arrow at the end. The translation start site is indicated with double lines with an arrow at the end. The genomic DNA fragment used in the rescue construct is indicated. (B) Schematic structures of the *Drosophila* *TSC1* and *TSC2* proteins. *TSC1* is a predicted 1100 aa polypeptide containing two coiled-coil domains (CC1 and CC2). The molecular lesions in *TSC1*¹² and *TSC1*²⁹ are indicated. *TSC2* is a predicted 1847 aa polypeptide containing a GAP domain.

TSC1 (Fig. 1). *TSC1*¹² and *TSC1*²⁹ are indistinguishable in their cell-size phenotype. All the subsequent analyses were performed by using the *TSC1*²⁹ allele.

TSC1 autonomously controls cell and organ size

Scanning electron microscopy revealed that the unit eyes (ommatidia) in *TSC1* mutant clones are larger than the surrounding wild-type ommatidia (Fig. 2A). Eye sections show that the rhabdomeres of mutant photoreceptors are approximately 1.8 times the size of neighboring wild-type counterparts in area ($n = 48$). However, the organization of ommatidia and the differentiation of various cell types are nearly normal, with occasional loss or gain of photoreceptor cells (Fig. 2B). Careful examination of mosaic ommatidia consisting of genetically marked *TSC1* mutant and nonmutant cells revealed that the effect of *TSC1* mutation on cell size is strictly cell autonomous (Fig. 2B). A similar autonomous effect on cell size is also observed in the wing (Fig. 2C). Therefore, *TSC1* autonomously controls cell size. To examine whether *TSC1* regulates organ size, we selectively removed *TSC1* function in the eye imaginal disc by using the *eyeless-FLP* technique (Newsome et al. 2000). This technique allowed us to consistently generate eye discs in which >90% of the cells are mutant for *TSC1*. Such eye discs are 2.9 times the size of wild-type discs in area ($n = 19$; Fig. 2D,E). Thus, *TSC1* autonomously controls organ size.

TSC1 controls cellular growth and proliferation during imaginal disc development

To examine when the cell size change occurs in *TSC1* mutant cells, we examined mutant clones in the imaginal discs. Larger nuclei and increased cell size in the mutant clones were evident in the third-instar imaginal discs (Fig. 3A–F), suggesting that cell size change oc-

curred during larval development. In addition, *TSC1* mutant (-/-) clones contained more cells than did their +/- twin spots (for example, see Fig 3A–C). To directly examine the cell proliferation defects of *TSC1*⁻ cells, we induced clones at 26 h, 50 h, and 74 h after egg deposition (AED) and quantitated cell numbers in the mutant clones and the twin spots at 119 h AED. The average ratio of cell numbers in *TSC1* mutant clones versus the twin spots was 3.1, 1.6, and 1.2 for clones induced at 26 h, 50 h, and 74 h AED, respectively ($n > 40$). Because the mutant clones and twin spots originate from mitotic sister cells born at the same developmental time, these results suggest that lack of *TSC1* affects cell proliferation, not just cell size. However, we cannot formally exclude the possibility that the increased cell number in the mutant clones is caused by decreased cell death of the mutant cells.

The nucleolus is the major site of ribosome assembly within the cell, and its size has been shown to correlate with protein synthesis and proliferation rate (Derenzini et al. 1998). We used an antibody against the nucleolar protein fibrillarin (Aris and Blobel 1988) to examine nucleolar size in *TSC1*⁻ cells. We found that the nucleolar area of *TSC1*⁻ cells in the wing imaginal disc was 2.1 times ($n = 70$) that of neighboring wild-type cells (Fig. 3G–I), consistent with a role for *TSC1* in cellular growth and proliferation.

Loss of TSC genes does not increase ploidy

Studies of the *Drosophila TSC2* gene suggested that *TSC2*⁻ cells undergo endoreplication, resulting in polyploidy and consequently increased cell size (Ito and Rubin 1999). To address whether a similar mechanism is responsible for the increased size of the *TSC1*⁻ cells, we examined DNA content in *TSC1*⁻ cells by using several different techniques: quantitative measurement of DNA dye Hoechst 33342 or propidium iodide staining in intact imaginal discs with confocal or fluorescent light micros-





Figure 2. *TSC1* autonomously controls cell and organ size. (A) Scanning electron micrograph of a compound eye carrying a clone of homozygous *TSC1*²⁹ cells. The mutant clone occupies the upper half of the eye in the picture. Note that the *TSC1* mutant ommatidia are larger than their wild-type counterparts. (B) Section through a *TSC1*²⁹ clone in the adult eye. The mutant clone is marked by the absence of pigment. The rhabdomeres of mutant photoreceptor cells are increased in area by about 80% compared with heterozygous photoreceptor cells (measured by Axiovision software). At the clone border, mosaic ommatidia containing normal-sized heterozygous cells (arrowhead) and enlarged homozygous *TSC1* mutant cells (arrow) can be seen, indicat-

ing that *TSC1* controls cell size autonomously. (C) Wing-margin bristles containing a *TSC1*²⁹ mutant clone. Note that the *TSC1* mutant bristles (marked by y' , indicated by a line above the wing margin) are thicker and longer than the wild-type bristles, which have a dark color. (D–E) Images of a wild-type eye-antenna disc (D) and an eye-antenna disc in which *TSC1* function was selectively removed in the eye by using the *ey-Flp* technique (E). The discs were also stained for *glass-lacZ* that is expressed in retinal cells. These images were taken under the same magnification. Note that the *TSC1*⁻ eye disc is much larger than the wild-type disc.

Figure 3. *TSC1* controls cellular growth and proliferation during imaginal disc development. In all panels, *TSC1* mutant clones were generated by FRT/FLP and marked by the absence of Ubi-GFP signal (green). (A–C) Confocal images of a third-instar eye disc containing a large *TSC1*[−] clone (arrow). The adjacent area of brighter green staining represents a +/+ twin spot (arrowhead). The disc was stained for the neuronal specific nuclear Elav protein (red). Three images are shown, one of GFP (A), one of Elav staining (B), and one of superimposed GFP and Elav staining (C). Note the increased size of the mutant cell nuclei and the dramatically increased area of the mutant clone as compared with its twin spot. (D–F) Confocal images of a portion of a third-instar eye disc containing *TSC1* mutant clones (arrows). The disc was stained with phalloidin (red), which highlights the outlines of the cells. Three images are shown, one of GFP (D), one of phalloidin staining (E), and one of superimposed GFP and phalloidin staining (F). Note the increased size of the mutant cells. (G–H) Confocal images of a portion of a third-instar wing disc containing a *TSC1* mutant clone (arrow). The disc was stained with fibrillarlin (red), which labels the nucleolus of the cells. Three images are shown, one of GFP (G), one of fibrillarlin staining (H), and one of superimposed GFP and fibrillarlin staining (I). Note the increased nucleolar size of the *TSC1*[−] cells.



copy, and FACS analysis of dissociated imaginal disc cells. We found that, surprisingly, *TSC1*[−] cells were diploid in DNA content (Fig. 4A,B). Although *TSC1* mutant nuclei are larger than their wild-type siblings, the relative intensity of DNA staining is weaker in the mutant cells, and the total fluorescence in the nuclei is comparable between the mutant and the wild-type cells (Fig. 4A,B). This observation prompted us to reexamine the DNA content of *TSC2*[−] cells. Similar to the results from the *TSC1*[−] cells, we observed total fluorescence of DNA dye staining in the *TSC2*[−] cells that was comparable with the wild-type cells (Fig. 4C,D). Consistent with microscopic measurement of DNA dye staining, FACS analysis of dissociated imaginal disc cells revealed similar DNA content in *TSC1*[−] or *TSC2*[−] cells as compared with the wild-type cells (Fig. 4E,F). These results suggest that loss of the *TSC* genes does not increase ploidy, and thus the increased size of *TSC1*[−] or *TSC2*[−] cells is not due to increased DNA content.

TSC1 and *TSC2* function in a common signaling pathway and form a stable complex in *Drosophila* cells

Based on their identical disease phenotypes, the human *TSC1* and *TSC2* genes have been proposed to function in a common signaling pathway. The *Drosophila* *TSC1* and *TSC2* mutants provided us with an opportunity to address this issue genetically. If *TSC1* and *TSC2* act in a common pathway, we might expect *TSC1* *TSC2* double-mutant cells to have an identical phenotype to that of

the *TSC1* or *TSC2* single mutant. Indeed, we observed that *TSC1* *TSC2* double-mutant cells show a cell size increase that is identical to that of *TSC1* or *TSC2* single-mutant cells (Fig. 5A–C), suggesting that these genes act in a common pathway that controls cellular growth. Human *TSC1* and *TSC2* proteins can associate with each other (van Slegtenhorst et al. 1998; Nellist et al. 1999). Given the identical phenotype of *TSC1*[−], *TSC2*[−], and *TSC1*[−] *TSC2*[−] cells, we suspected that *Drosophila* *TSC1* and *TSC2* proteins might also associate with each other. To investigate this possibility, we performed coimmunoprecipitation assays in *Drosophila* S2 cells that expressed *TSC1* and *TSC2* proteins tagged with Myc and V5 epitopes, respectively (Fig. 5D). These experiments revealed a specific interaction between *TSC1* and *TSC2* (Fig. 5E). Furthermore, we mapped the interaction domain to the N-terminal half of *TSC2* (Fig. 5E), consistent with studies of the human *TSC2* protein (van Slegtenhorst et al. 1998). Taken together, these results suggest that *TSC1* and *TSC2* function in a protein complex to regulate cellular growth in *Drosophila*.

Coexpression of *Drosophila* *TSC1* and *TSC2*, but not either gene alone, reduces cell and organ size

We used the *GAL4-UAS* system (Brand and Perrimon 1993) to assess the effect of overexpressing *TSC1* and *TSC2* on cellular growth. *Drosophila* *TSC1*, *TSC2*, or a combination of both gene products, was expressed from *UAS* transgenes under the control of the *GAL4* driver




Figure 4. *TSC1*⁻ and *TSC2*⁻ cells are diploid. In A–D, mutant clones were generated by FRT/FLP and marked by the absence of Ubi-GFP signal (green). (A–B) Confocal images of a portion of a third-instar eye disc containing two *TSC1*⁻ clones (arrows). The disc was stained with DNA dye propidium iodide (PI, shown in red). Two images are shown, one of GFP (A) and one of PI staining (B). Note that the intensity of PI staining is weaker in the mutant cells. Quantitation of Z series by using LSM 510 software showed that the total fluorescence in the nuclei is comparable between the mutant and the wild-type cell (data not shown). (C–D) Fluorescent light microscopy images of a portion of a third-instar eye disc containing a *TSC2* (*gigas*) mutant clone (arrow). The disc was stained with DNA dye Hoechst 33342 (blue). Note that the intensity of Hoechst 33342 staining is weaker in the mutant cells. Quantitation by using the Axiovision software showed that the total fluorescence in the nuclei is comparable between the mutant and the wild-type cell (data not shown). (E–F) Flow cytometric analysis of dissociated wing imaginal discs containing *TSC1*⁻ (E) and *TSC2*⁻ (F) clones. The profiles of mutant and wild-type (WT) cells are indicated by heavy and light traces, respectively. No signal was detected beyond the DNA content of cycling diploid cells (data not shown). Note that the DNA content of *TSC1*⁻ or *TSC2*⁻ cells is similar to that of wild-type cells.

line *MS1096*, which expresses high levels of GAL4 near uniformly in the wing-pouch region (Capdevila and Guerrero 1994). Although overexpression of *TSC1* or *TSC2* alone did not result in any visible phenotype, co-expression of both genes resulted in a dramatic reduction in wing size (Fig. 5F–H). Quantitation of wing size and

wing-hair density revealed a 72% reduction in wing size and a 65% reduction in cell size ($n = 20$). Thus, most of the wing-size reduction can be accounted for by the reduction in cell size. We suggest that *TSC1* and *TSC2* function as a complex in vivo and are present at rate-limiting concentrations as a protein complex. Thus only simultaneous overexpression of both proteins, but not either protein alone, can increase the concentration of the *TSC1*–*TSC2* protein complex, which in turn results in cell growth suppression that is opposite of the loss-of-function phenotype.

TSC genes act in a parallel pathway that converges on the insulin pathway downstream from Akt

The insulin pathway is known to play a central role in the control of cellular growth in *Drosophila* (for review, see Stocker and Hafen 2000). The loss-of-function and gain-of-function phenotypes of the *TSC* genes are strikingly similar to those of *PTEN*, a negative regulator of the InR-PI3K-Akt pathway (Goberdhan et al. 1999; Huang et al. 1999; Gao et al. 2000). This prompted us to investigate the relationship between the *TSC* genes and components of the insulin pathway. Previous studies have shown that loss of *inr* or *Akt* leads to decreased cell size. To investigate the relationship between *inr*, *Akt*, and the *TSC* genes, we examined *TSC1 Akt* and *TSC1 inr* double-mutant clones. Cells homozygous for a strong allele of *inr* (*inr*³⁵; Fernandez et al. 1995), or a null allele of *Akt* (*Akt1*^q; Staveley et al. 1998) are smaller, and are rarely recovered in adult eye clones because of cell competition during development (Fig. 6A,B; also see Verdu et al. 1999). However, *TSC1 inr*³⁵ or *TSC1 Akt1*^q double-mutant cells showed a similar cell size increase as that observed in *TSC1*⁻ cells (Fig. 6A–E). Furthermore, the competitive disadvantage of *inr* and *Akt* mutant cells was also rescued in the *TSC1 inr*³⁵ or *TSC1 Akt1*^q double-mutant clones, resulting in larger clones that contained more cells (Fig. 6A–D and data not shown). This result suggests that *TSC1* acts genetically downstream from Akt. This observation is compatible with either *TSC1* acting molecularly downstream from Akt in the linear InR-PI3K-Akt pathway, or *TSC1* acting in a parallel pathway that converges on the insulin pathway downstream from Akt.

To distinguish between these two possibilities, we generated cells that are doubly mutant for null alleles of *PTEN* and *TSC1*. *PTEN* is a negative regulator of the InR-PI3K-Akt pathway, and loss of *PTEN* results in increased Akt activity and cellular growth. We reasoned that if *TSC1* acts downstream from Akt within the InR-PI3K-Akt pathway, we might expect *PTEN TSC1* double-mutant cells to show a similar cell-size phenotype to either single mutant. However, if *TSC1* acts parallel to the InR-PI3K-Akt pathway, we might expect *PTEN TSC1* double-mutant cells to show additive effects on cell size as compared with each single mutant. We observed that *PTEN TSC1* double-mutant photoreceptors are 2.9 times the size of wild-type cells, as compared with 1.9 for *PTEN*⁻ and 1.8 for *TSC1*⁻ ($n = 50$). This result




Figure 5. Interactions between TSC1 and TSC2. (A–C) Wing margins containing *TSC1*^{-/-} (A), *TSC2*^{-/-} (B), and *TSC1*^{-/-}*TSC2*^{-/-} (C) clones, respectively. Note that *TSC* single- or double-mutant bristles (marked by *y*⁻, indicated by a line above the wing margin) are similar in size. (D) Schematic representation of epitope-tagged TSC1 and TSC2 proteins that were expressed in S2 cells. The TSC1 construct corresponds to the full-length protein and migrates as an ~150-kD protein. Three TSC2 constructs were generated, including the full-length (TSC2, >200 kD), N-terminal half (TSC2N, ~130 kD), and C-terminal half (TSC2C, ~130 kD). (E) S2 cells expressing TSC1/TSC2, TSC1/TSC2N, and TSC1/TSC2C constructs were lysed and total cell lysate was immunoprecipitated (IP) with α-MYC and immunoblotted with α-V5 (left panel). TSC2 or TSC2N, but not TSC2C, can be immunoprecipitated with TSC1. The same blot was stripped and reprobed with α-MYC to show that TSC1 was expressed at comparable levels in all lanes (middle panel). As an additional control, TSC2, TSC2N, and TSC2C were precipitated from the same cell lysate by using Ni-NTA agarose (α-His) and probed with α-V5. These proteins were expressed at comparable levels (right panel). (F–H) Wings expressing *MS1096/UAS-TSC1* (F), *MS1096/UAS-TSC2* (G), and *MS1096/UAS-TSC1; UAS-TSC2*, respectively. These images were taken under the same magnification. Wings overexpressing both *TSC1* and *TSC2* are ~28% the size of wings expressing *TSC1* or *TSC2* alone.

strongly suggests that the *TSC* genes function in a parallel pathway that converges on the insulin pathway at a point downstream from Akt.

Heterozygosity of TSC1 or TSC2 rescues the lethality of loss-of-function InR mutants

In the course of our studies, we observed a striking genetic interaction between the *TSC* genes and *inr* mutations. Flies homozygous for *inr*³⁵, a strong loss-of-function allele, are larval lethal (Fernandez et al. 1995). However, homozygous *inr*³⁵ flies that are heterozygous for *TSC1* can survive to adults (Table 1), suggesting that a mere 50% reduction in the dosage of the *TSC1* gene can rescue the developmental arrest of an *inr* mutant.

Similarly, heterozygosity of *TSC2* is sufficient to rescue the lethality of another *inr* mutant (Table 1). Flies carrying the allelic combination *inr*³⁵³/*inr*^{l(3)05545} are 100% lethal (Fernandez et al. 1995). However, approximately 39% of *inr*³⁵³/*inr*^{l(3)05545} flies that are heterozygous for *TSC2* can survive to adults (Table 1). Taken together, these results provide convincing *in vivo* evi-

dence that the *TSC* genes are negative regulators of insulin signaling in development.

Discussion

The mechanisms of how body and organ size are regulated are largely unknown (for review, see Conlon and Raff 1999). Recent genetic studies in *Drosophila* suggest that the insulin pathway may coordinately control both cell growth and cell proliferation and in turn regulate organ size. Here, we have provided evidence that the *TSC* tumor suppressor genes also play an essential role in the control of cell size and organ size. Although an increase in cell size has been observed in human tumors carrying *TSC1* or *TSC2* mutations (for review, see Young and Povey 1998), the underlying mechanisms are not clear. Our results suggest that the *TSC* genes and the insulin pathway act antagonistically in the control of cellular growth. Loss of *TSC* genes resulted in a cell-size phenotype that is almost identical to that of *PTEN*. Similarly, co-overexpression of the *TSC* genes reduces cell size as *PTEN* overexpression. The results from our




Figure 6. The *TSC* genes act in a parallel pathway that converges on the insulin pathway downstream from Akt. Eye sections of various mutant clones. The genotype of the mutant clone is labeled below each section, as well as the relative size of the mutant rhabdomeres as compared with the wild-type counterparts (X value). At least 50 ommatidia were measured in each genotype. Mutant clones were marked by the absence of pigment, and the borders of mutant clones were outlined with red lines. Although *inr*⁻ or *akt*⁻ clones contain few cells, *TSC1*⁻ *inr*⁻, or *TSC1*⁻ *akt*⁻ clones contain many more cells (only portions of the mutant clones are shown in C and D). (A) *inr*⁻. (B) *akt*⁻. (C) *TSC1*⁻ *inr*⁻. (D) *TSC1*⁻ *akt*⁻. (E) *TSC1*⁻. (F) *PTEN*⁻. (G) *TSC1*⁻ *PTEN*⁻.

double-mutant analyses suggest that the *TSC* genes act in a pathway parallel to the insulin pathway, and the *TSC* pathway converges on the insulin pathway downstream from Akt. Several proteins are known to function directly downstream from Akt, or to converge on the insulin pathway downstream from Akt. These include

Table 1. Heterozygosity of *TSC1* or *TSC2* rescues the lethality of loss-of-function insulin-receptor mutants

Genotype	Animals surviving to pupal stage (%)	Animals surviving to adult stage (%)
<i>inr</i> ³⁵		
<i>inr</i> ³⁵	0	0
<i>inr</i> ³⁵ <i>TSC1</i> ²⁹		
<i>inr</i> ³⁵ +	56	6.6
<i>inr</i> ³⁵³		
<i>inr</i> ¹⁽³⁾⁰⁵⁵⁴⁵	ND	0
<i>inr</i> ³⁵³ <i>TSC2</i> ¹⁹²		
<i>inr</i> ¹⁽³⁾⁰⁵⁵⁴⁵ +	ND	39

In the cross between *inr*³⁵ *TSC1*²⁹ and *inr*³⁵, 191 flies were scored.

In the cross between *inr*³⁵³ *TSC2*¹⁹² and *inr*¹⁽³⁾⁰⁵⁵⁴⁵, 110 flies were scored.

(ND) Not determined.

S6K (Thomas and Hall 1997), 4E-BP (Sonenberg and Gingras 1998), and Ser/Thr kinase TOR (Schmelzle and Hall 2000). Our genetic analysis is consistent with the *TSC* pathway regulating any of these candidate proteins. Alternatively, the *TSC* genes may regulate unknown regulators of cell growth. We cannot distinguish between these models at present.

Our most convincing evidence for a functional link between the *TSC* genes and insulin signaling came from the observation that heterozygosity of *TSC1* or *TSC2* is sufficient to rescue the lethality of loss-of-function InR mutants. This argues that the *TSC* genes are intimately linked to insulin signaling, rather than functioning in a totally independent cell-growth pathway. These results suggest that the *TSC* tumor suppressor genes are novel negative regulators of insulin signaling, and modulating the activities of the *TSC* genes might provide a potential way to correct insulin signaling defects in certain diseases such as diabetes and obesity.

An important challenge in the future is to understand the molecular mechanism by which the *TSC* tumor suppressors regulate the insulin pathway. The predicted structures of the *TSC1* (containing coiled-coil domains) and the *TSC2* protein (containing a GAP domain) offer clues in that regard. The *TSC2* protein has been shown to possess GAP activity toward two small GTPases, Rab5 and Rap1 (Wienecke et al. 1995; Xiao et al. 1997). Rab5 is a rate-limiting component of the endocytic path-

way (Bucci et al. 1992). It has been speculated that loss of the TSC tumor suppressors could lead to missorting of internalized growth factor receptors or other signal-mediated membrane-bound molecules that would otherwise undergo lysosomal degradation, thus leading to a constitutive activation of certain growth-promoting pathways (Xiao et al. 1997). The *in vivo* function of Rap1 is largely unknown, and Rap1 can function both as positive and negative regulator of cell proliferation under different conditions (Kitayama et al. 1989; Yoshida et al. 1992). Further studies of the *Drosophila* TSC genes may provide insights into the relative importance of Rab5GAP and Rap1GAP activities in growth suppression.

Materials and methods

Molecular biology

Genomic DNA was isolated from the *TSC1* mutant embryos and amplified with PCR. The PCR products were directly sequenced by using primers spanning the *TSC1* locus. This analysis revealed point mutations in the *TSC1*¹² and the *TSC1*²⁹ allele (Fig. 1B). A 4.7-kb genomic fragment containing just the *TSC1* transcription unit was cloned into Casperhs-1, a modified Casperhs vector (Pan and Rubin 1997), for the rescue experiment.

A full-length *TSC1* cDNA clone, LD24327, was obtained from Research Genetics, and used to generate UAS-*TSC1* construct.

Myc-tagged *TSC1* and V5/His-tagged *TSC2* constructs were made by using pAc5.1/V5-HisB vector (Invitrogen). Sequences encoding the N-terminal Myc epitope (MEQKLISEEDLNE) was added by PCR in place of the first Met codon of a full-length *TSC1* cDNA.

Drosophila strains

*TSC2*¹⁹² (*gig*¹⁹²), a null *TSC2* allele, and UAS-*TSC2* flies were kindly provided by Naoto Ito (Ito and Rubin 1999). *inr*³⁵ and *inr*³⁵³ (strong alleles) were gifts from Manfred Frasch (Fernandez et al. 1995). *Akt*^q, a kinase-dead null allele of *Akt*, was kindly provided by Armen Manoukian (Staveley et al. 1998). *PTEN*^{di189} is a null allele (Gao et al. 2000). Genotypes for generating clones are as follows.

TSC1 mutant clones: *y w hsp-flp; TSC1*²⁹ *FRT82B/FRT82B*, *w*⁺ for adult eyes
*y w hsp-flp; TSC1*²⁹ *FRT82B/FRT82B*, *y*⁺ for adult wings
*yw hsp-flp; TSC1*²⁹ *FRT82B/FRT82B*, *Ubi-GFP*⁺ for imaginal discs

ey-Flp *TSC1*: *y w ey-flp glass-lacZ; TSC1*²⁹ *FRT82B/FRT82B*, *w*⁺ *cl3R3*

TSC2 mutant clones: *yw hsp-flp; TSC2*¹⁹² *FRT80B/FRT80B*, *Ubi-GFP*⁺ for imaginal discs

TSC1 TSC2 double-mutant clones (marked by *y*): *y w hsp-flp; TSC2*¹⁹² *FRT80B TSC1*²⁹/*y*⁺ *P[TSC1*⁺] *FRT80B TSC1*²⁹ for adult wings

TSC1 Akt double-mutant clones (marked by *w*): *y w hsp-flp; FRT82B Akt*^q *TSC1*²⁹/*FRT82B w*⁺ for adult eyes

TSC1 inr double-mutant clones (marked by *w*): *y w hsp-flp; FRT82B TSC1*²⁹ *inr*³⁵/*FRT82B w*⁺ for adult eyes

PTEN mutant clones (marked by *w*): *y w hsp-flp; PTEN*^{di189} *FRT40A/FRT40A*, *y*⁺ *w*⁺ for adults

TSC1 PTEN double-mutant clones (marked by *w*): *y w hsp-flp; PTEN*^{di189}/*PTEN*^{di189}; *FRT82B TSC1*²⁹/*FRT82B w*⁺ *P[PTEN*⁺] for adult eyes

Cell transfection and immunoprecipitation

S2 cells are transfected by using the Calcium Phosphate method (Invitrogen). Cells were lysed in cold immunoprecipitation buffer (1% Triton X-100, 0.5% NP-40, 150mM NaCl, 10mM Tris at pH 7.4, 1mM EDTA, 1mM EGTA, 0.2mM PMSF). Immunoprecipitation was performed by using anti-Myc antibody (Santa Cruz Biotechnology) and protein G Sepharose according to manufacturer's instruction.

Flow cytometry

FACS analysis of dissociated imaginal wing disc cells was performed as previously described (Neufeld et al. 1998). *TSC1* or *TSC2* homozygous mutant clones induced by FLP/FRT-mediated recombination were marked by their lack of GFP expression by using ubiquitin-GFP FRT chromosomes (donated to the Bloomington stock center by Bruce Edgar). FACS sorting was performed on a FACStar machine and analyzed with CellQuest program.

Histology and microscopy

Clones of mutant cells were generated by FLP/FRT-mediated mitotic recombination (Xu and Rubin 1993). Immunostaining of imaginal discs was performed as described by Xu and Rubin (1993). Antifibrillar antibody was a gift of John Aris (Aris and Blobel 1988). Confocal images were collected by using a Zeiss LSM 510 confocal microscope and analyzed by using LSM 510 software. Light-microscopy images were acquired on a Zeiss Axioplan microscope equipped with an AxioCam digital camera and analyzed by using the Axiovision software.

Acknowledgments

We thank Elizabeth Chen, Jin Jiang, and Keith Wharton for critical reading of the manuscript. We also thank the Bloomington Stock Center, Developmental Studies Hybridoma Bank, Manfred Frasch, Naoto Ito, and John Aris for fly stocks and reagents, and the UT Southwestern Molecular and Cellular Imaging Facility for assistance with eye sections. D.J.P. is Virginia Murchison Linthicum Endowed Scholar in Medical Science, and is supported by NIH (GM62323) and AHA (0130222N).

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Aris, J. P. and Blobel, G. 1988. Identification and characterization of a yeast nucleolar protein that is similar to a rat liver nucleolar protein. *J. Cell Biol.* **107**: 17–31.
- Böhni, R., Riesgo-Escovar, J., Oldham, S., Brogiolo, W., Stocker, H., Andruss, B.F., Beckingham, K., and Hafen, E. 1999. Au-

- tonomous control of cell and organ size by CHICO, a *Drosophila* homolog of vertebrate IRS1–4. *Cell* **97**: 865–875.
- Brand, A.H. and Perrimon, N. 1993. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**: 401–415.
- Bucci, C., Parton, R.G., Mather, I.H., Stunnenberg, H., Simons, K., Hoflack, B., and Zerial, M. 1992. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. *Cell* **70**: 715–728.
- Cantley, L.C. and Neel, B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase / AKT pathway. *Proc. Natl. Acad. Sci.* **96**: 4240–4245.
- Capdevila, J. and Guerrero, I. 1994. Targeted expression of the signaling molecule decapentaplegic induces pattern duplications and growth alterations in *Drosophila* wings. *EMBO J.* **13**: 4459–4468.
- Chen, C., Jack, J., and Garofalo, R.S. 1996. The *Drosophila* insulin receptor is required for normal growth. *Endocrinology* **137**: 846–856.
- Conlon, I. and Raff, M. 1999. Size control in animal development. *Cell* **96**: 235–244.
- Derenzini, M., Trere, D., Pession, A., Montanaro, L., Sirri, V., and Ochs, R.L. 1998. Nuclear function and size in cancer cells. *Am. J. Pathol.* **152**: 1291–1297.
- The European Chromosome 16 Tuberous Sclerosis Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* **75**: 1305–1315.
- Fernandez, R., Tabarini, D., Azpiazu, N., Frasch, M., and Schlessinger, J. 1995. The *Drosophila* insulin receptor homolog: A gene essential for embryonic development encodes two receptor isoforms with different signaling potential. *EMBO J.* **14**: 3373–3384.
- Gao, X., Neufeld, T.P., and Pan, D. 2000. *Drosophila* PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. *Dev. Biol.* **221**: 404–418.
- Goberdhan, D.C.I., Paricio, N., Goodman, E.C., Mlodzik, M., and Wilson, C. 1999. *Drosophila* tumor suppressor *PTEN* controls cell size and number by antagonizing the Chico / PI3-kinase signaling pathway. *Genes & Dev.* **13**: 3244–3258.
- Henry, K.W., Yuan, X., Koszewski, N.J., Onda, H., Kwiatkowski, D.J., and Nordstrom, W. 1998. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. *J. Biol. Chem.* **273**: 20535–20539.
- Huang, H., Potter, C.J., Tao, W., Li, D.-M., Brogiolo, W., Hafen, E., Sun, H., and Xu, T. 1999. PTEN affects cell size, cell proliferation and apoptosis during *Drosophila* eye development. *Development* **126**: 5365–5372.
- Ito, N. and Rubin, G.M. 1999. *gigas*, a *Drosophila* homolog of tuberous sclerosis gene product-2, regulates the cell cycle. *Cell* **96**: 529–539.
- Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y., and Noda, M. 1989. A ras-related gene with transformation suppressor activity. *Cell* **56**: 77–84.
- Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. 1999. Renal carcinogenesis, hepatic hemangiomas, and embryonic lethality caused by a germ-line *Tsc2* mutation in mice. *Cancer Res.* **59**: 1206–1211.
- Kobayashi, T., Mitani, H., Takahashi, R.-I., Hirabayashi, M., Ueda, M., Tamura, H., and Hino, O. 1997. Transgenic rescue from embryonic lethality and renal carcinogenesis in the Eker rat model by introduction of a wild-type *Tsc2* gene. *Proc. Natl. Acad. Sci.* **94**: 3990–3993.
- Lamb, R.S., Roy, C., Diefenbach, T.J., Vinters, H.V., Johnson, M.W., Jay, D.G., and Hall, A. 2000. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. *Nature Cell Biol.* **2**: 281–287.
- Montagne, J., Stewart, M.J., Stocker, H., Hafen, E., Kozma, S.C., and Thomas, G. 1999. *Drosophila* S6 kinase: A regulator of cell size. *Science* **285**: 2126–2129.
- Nellist, M., van Slegtenhorst, M., Goedbloed, M., van den Ouweland, A., Halley, D., and van der Sluijs, P. 1999. Characterization of the cytosolic tuberlin-hamartin complex. Tuberlin is a cytosolic chaperone for hamartin. *J. Biol. Chem.* **274**: 35647–35652.
- Neufeld, T.P., de la Cruz, A.F.A., Johnston, L.A., and Edgar, B.A. 1998. Coordination of growth and cell division in the *Drosophila* wing. *Cell* **93**: 1183–1193.
- Newsome, T.P., Asling, B., and Dickson, B.J. 2000. Analysis of *Drosophila* photoreceptor axon guidance in eye-specific mosaics. *Development* **127**: 851–860.
- Oldham, S., Montagne, J., Radimerski, T., Thomas, G., and Hafen, E. 2000. Genetic and biochemical characterization of dTOR, the *Drosophila* homolog of the target of rapamycin. *Genes & Dev.* **14**: 2689–2694.
- Onda, H., Lueck, A., Marks, P.W., Warren, H.B., and Kwiatkowski, D.J. 1999. *Tsc2*^{+/-} mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. *J. Clin. Invest.* **104**: 687–695.
- Pan, D. and Rubin, G.M. 1997. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during *Drosophila* and vertebrate neurogenesis. *Cell* **90**: 271–280.
- Proud, C.G. and Denton, R.M. 1997. Molecular mechanisms for the control of translation by insulin. *Biochem. J.* **328**: 329–341.
- Rennebeck, G., Kleymenova, E.V., Anderson, R., Yeung, R.S., Artzt, K., and Walker, C.L. 1998. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. *Proc. Natl. Acad. Sci.* **95**: 15629–15634.
- Schmelzle, T. and Hall, M.N. 2000. TOR, a central Controller of cell growth. *Cell* **103**: 253–262.
- Sonenberg, N. and Gingras, A.-C. 1998. The mRNA 5' cap-binding protein eIF4E and control of cell growth. *Curr. Opin. Cell Biol.* **10**: 268–275.
- Soucek, T., Pusch, O., Wienecke, R., DeClue, J.E., and Hengstschläger, M. 1997. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. *J. Biol. Chem.* **272**: 29301–29308.
- Soucek, T., Yeung, R.S., and Hengstschläger, M. 1998. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. *Proc. Natl. Acad. Sci.* **95**: 15653–15658.
- Staveley, B.E., Ruel, L., Jin, J., Stambolic, V., Mastronardi, F.G., Heitzler, P., Woodgett, J.R., and Manoukian, A.S. 1998. Genetic analysis of protein kinase B (AKT) in *Drosophila*. *Curr. Biol.* **8**: 599–602.
- Stocker, H. and Hafen, E. 2000. Genetic control of cell size. *Curr. Opin. Genet. Dev.* **10**: 529–535.
- Su, T.T. and O'Farrell, P.H. 1998. Size control: Cell proliferation does not equal growth. *Curr. Biol.* **8**: R687–R689.
- Thomas, G. and Hall, M.N. 1997. TOR signalling and control of cell growth. *Curr. Opin. Cell Biol.* **9**: 782–787.
- van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J., et al. 1997. Identification of the tuberous sclerosis gene *TSC1* on chromosome 9q34. *Science* **277**: 805–808.
- van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Chedale,

Gao and Pan

- J.P., Snell, R.G., van den Ouweland, A., Reuser, A., Sampson, J.R., Halley, D., and van der Sluijs, P. 1998. Interaction between hamartin and tuberlin, the *TSC1* and *TSC2* gene products. *Hum. Mol. Genet.* **7**: 1053–1057.
- Verdu, J., Buratovich, M.A., Wilder, E.L., and Birnbaum, M.J. 1999. Cell-autonomous regulation of cell and organ growth in *Drosophila* by Akt/PKB. *Nature Cell Biol.* **1**: 500–506.
- Weinkove, D., Neufeld, T.P., Twardzik, T., Waterfield, M.D., and Leever, S.J. 1999. Regulation of imaginal disc cell size, cell number and organ size by *Drosophila* class I_A phosphoinositide 3-kinase and its adaptor. *Curr. Biol.* **9**: 1019–1029.
- Wienecke, R., Konig, A., and DeClue, J.E. 1995. Identification of tuberlin, the Tuberous Sclerosis-2 product: tuberlin possesses specific Rap1GAP activity. *J. Biol. Chem.* **270**: 16409–16414.
- Xiao, G.-H., Shoarinejad, F., Jin, F., Golemis, E.A., and Yeung, R.S. 1997. The tuberous sclerosis 2 gene product, tuberlin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. *J. Biol. Chem.* **272**: 6097–6100.
- Xu, T. and Rubin, G.M. 1993. Analysis of genetic mosaics in developing and adult *Drosophila* tissues. *Development* **117**: 1223–1237.
- Yoshida, Y., Kawata, M., Miura, Y., Sasaki, T., Kikuchi, A., and Takai, Y. 1992. Microinjection of smg/rap1/Krev-1 p21 into Swiss 3T3 cells induced DNA synthesis and morphological changes. *Mol. Cell Biol.* **12**: 3407–3414.
- Young, J. and Povey, S. 1998. The genetic basis of tuberous sclerosis. *Mol. Med. Today* **4**: 313–319.
- Zhang, H., Stallock, J.P., Ng, J.C., Reinhard, C., and Neufeld, T.P. 2000. Regulation of cellular growth by the *Drosophila* target of rapamycin *dTOR*. *Genes & Dev.* **14**: 2712–2724.



***TSC1* and *TSC2* tumor suppressors antagonize insulin signaling in cell growth**

Xinsheng Gao and Duoqia Pan

Genes Dev. 2001, **15**:

Access the most recent version at doi:[10.1101/gad.901101](https://doi.org/10.1101/gad.901101)

References

This article cites 46 articles, 21 of which can be accessed free at:
<http://genesdev.cshlp.org/content/15/11/1383.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

horizon
a PerkinElmer company

Streamline your research with
Horizon Discovery's ASO tool

The advertisement features a dark blue background with a glowing DNA double helix structure on the left. The text is white and positioned on the right side of the banner.